Clinical trial · Interventional
Mannitol Brain Relaxation Effect
Can Mannitol Increments Provide More Brain Relaxation in Patients Undergoing Craniotomy for Supratentorial Brain Tumor Removal?
NCT02168075CI-TRIAL-00015898MANNITOLunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Mannitol is widely used in patients with elevated intracranial pressure. In neurosurgical field, especially in large size or with brain edema, it is necessary to decrease brain volume to facilitate surgical approach. In general, 0.25 -1.5g of mannitol per kilogram has been known to decrease ICP effectively. But there are some debates in regard to appropriate dose of mannitol.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Supratentorial Neoplasms | Supratentorial Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 0.25g/kgof 20% mannitol | Drug | — | UNRESOLVED |
| 0.5g/kg of 20% mannitol | Drug | — | UNRESOLVED |
| 1.0g/kg of 20% mannitol | Drug | — | UNRESOLVED |
| 1.5g/kg of 20% mannitol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Group 1
- description
- 0.25g/kgof 20% mannitol administered at drilling of skull.
- interventionNames
- Drug: 0.25g/kgof 20% mannitol
- type
- EXPERIMENTAL
- label
- Group 2
- description
- 0.5g/kg of 20% mannitol administered at drilling of skull.
- interventionNames
- Drug: 0.5g/kg of 20% mannitol
- type
- EXPERIMENTAL
- label
- Group 3
- description
- 1.0 g/kg of 20% mannitol administered at drilling of skull.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who underwent craniotomy for supratentorial brain tumor under general anesthesia Exclusion Criteria: * Patient who does not agree to the study * Patients with or American Society of Anesthesiologists (ASA) physical status class IV or more * Patients with glasgow coma scale (GCS) under 13 points * Patients who have hyponatremia or hypernatremia (Na\<130 or \>150mEq/L) * Patients who have congestive heart failure or moderately decreased renal function (GFR \<60ml/min/1.73m2) * Patients with extraventricular drainage such as external ventricular drain (EVD) or ventriculoperitoneal (VP) shunt * Patients who already under mannitolization
References
Publications (1)
- DERIVEDSeo H, Kim E, Jung H, Lim YJ, Kim JW, Park CK, Se YB, Jeon YT, Hwang JW, Park HP. A prospective randomized trial of the optimal dose of mannitol for intraoperative brain relaxation in patients undergoing craniotomy for supratentorial brain tumor resection. J Neurosurg. 2017 Jun;126(6):1839-1846. doi: 10.3171/2016.6.JNS16537. Epub 2016 Aug 19. PMID 27540904